Literature DB >> 33542232

Engineering advanced logic and distributed computing in human CAR immune cells.

Jang Hwan Cho1,2, Atsushi Okuma1,2, Katri Sofjan1,2, Seunghee Lee1,2, James J Collins3,4,5,6,7,8, Wilson W Wong9,10.   

Abstract

The immune system is a sophisticated network of different cell types performing complex biocomputation at single-cell and consortium levels. The ability to reprogram such an interconnected multicellular system holds enormous promise in treating various diseases, as exemplified by the use of chimeric antigen receptor (CAR) T cells as cancer therapy. However, most CAR designs lack computation features and cannot reprogram multiple immune cell types in a coordinated manner. Here, leveraging our split, universal, and programmable (SUPRA) CAR system, we develop an inhibitory feature, achieving a three-input logic, and demonstrate that this programmable system is functional in diverse adaptive and innate immune cells. We also create an inducible multi-cellular NIMPLY circuit, kill switch, and a synthetic intercellular communication channel. Our work highlights that a simple split CAR design can generate diverse and complex phenotypes and provide a foundation for engineering an immune cell consortium with user-defined functionalities.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33542232      PMCID: PMC7862674          DOI: 10.1038/s41467-021-21078-7

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  48 in total

1.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

Review 2.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Authors:  Spencer C Wei; Colm R Duffy; James P Allison
Journal:  Cancer Discov       Date:  2018-08-16       Impact factor: 39.397

3.  Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Authors:  Fabiana Perna; Samuel H Berman; Rajesh K Soni; Jorge Mansilla-Soto; Justin Eyquem; Mohamad Hamieh; Ronald C Hendrickson; Cameron W Brennan; Michel Sadelain
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

4.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

5.  Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.

Authors:  Verena Staedtke; Ren-Yuan Bai; Kibem Kim; Martin Darvas; Marco L Davila; Gregory J Riggins; Paul B Rothman; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Nature       Date:  2018-12-12       Impact factor: 49.962

6.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.

Authors:  S Zhang; C Cordon-Cardo; H S Zhang; V E Reuter; S Adluri; W B Hamilton; K O Lloyd; P O Livingston
Journal:  Int J Cancer       Date:  1997-09-26       Impact factor: 7.396

7.  γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes.

Authors:  Irma Airoldi; Alice Bertaina; Ignazia Prigione; Alessia Zorzoli; Daria Pagliara; Claudia Cocco; Raffaella Meazza; Fabrizio Loiacono; Barbarella Lucarelli; Maria Ester Bernardo; Giulia Barbarito; Daniela Pende; Alessandro Moretta; Vito Pistoia; Lorenzo Moretta; Franco Locatelli
Journal:  Blood       Date:  2015-01-22       Impact factor: 22.113

8.  GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.

Authors:  Okjae Lim; Yuna Lee; Hyejin Chung; Jung Hyun Her; Sang Mi Kang; Mi-young Jung; Bokyung Min; Hyejin Shin; Tae Min Kim; Dae Seog Heo; Yu Kyeong Hwang; Eui-Cheol Shin
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

Review 9.  Treg and CTLA-4: two intertwining pathways to immune tolerance.

Authors:  Lucy S K Walker
Journal:  J Autoimmun       Date:  2013-07-10       Impact factor: 7.094

10.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.

Authors:  Christopher C Kloss; Maud Condomines; Marc Cartellieri; Michael Bachmann; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2012-12-16       Impact factor: 54.908

View more
  15 in total

Review 1.  Application and Design of Switches Used in CAR.

Authors:  Paweł Głowacki; Piotr Rieske
Journal:  Cells       Date:  2022-06-13       Impact factor: 7.666

2.  Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control.

Authors:  Ian C Miller; Ali Zamat; Lee-Kai Sun; Hathaichanok Phuengkham; Adrian M Harris; Lena Gamboa; Jason Yang; John P Murad; Saul J Priceman; Gabriel A Kwong
Journal:  Nat Biomed Eng       Date:  2021-08-12       Impact factor: 25.671

Review 3.  Mechanisms of immune activation and regulation: lessons from melanoma.

Authors:  Shelly Kalaora; Adi Nagler; Jennifer A Wargo; Yardena Samuels
Journal:  Nat Rev Cancer       Date:  2022-02-01       Impact factor: 69.800

Review 4.  The evolution of synthetic receptor systems.

Authors:  Janvie Manhas; Hailey I Edelstein; Joshua N Leonard; Leonardo Morsut
Journal:  Nat Chem Biol       Date:  2022-01-20       Impact factor: 16.174

5.  Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.

Authors:  Talar Tokatlian; Grace E Asuelime; Jee-Young Mock; Breanna DiAndreth; Shruti Sharma; Dora Toledo Warshaviak; Mark E Daris; Kristian Bolanos; Breanna L Luna; Martin S Naradikian; Kiran Deshmukh; Agnes E Hamburger; Alexander Kamb
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

Review 6.  Implementing Logic Gates for Safer Immunotherapy of Cancer.

Authors:  Mohammed Azharuddin Savanur; Hadas Weinstein-Marom; Gideon Gross
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

7.  Robust In Vitro Pharmacology of Tmod, a Synthetic Dual-Signal Integrator for Cancer Cell Therapy.

Authors:  Diane Manry; Kristian Bolanos; Breanna DiAndreth; Jee-Young Mock; Alexander Kamb
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

Review 8.  CAR T Cell Immunotherapy Beyond Haematological Malignancy.

Authors:  Cedric Hupperetz; Sangjoon Lah; Hyojin Kim; Chan Hyuk Kim
Journal:  Immune Netw       Date:  2022-02-11       Impact factor: 5.851

Review 9.  CAR T cells: Building on the CD19 paradigm.

Authors:  Anat Globerson Levin; Isabelle Rivière; Zelig Eshhar; Michel Sadelain
Journal:  Eur J Immunol       Date:  2021-08-02       Impact factor: 6.688

Review 10.  Theranostic cells: emerging clinical applications of synthetic biology.

Authors:  Monica P McNerney; Kailyn E Doiron; Tai L Ng; Timothy Z Chang; Pamela A Silver
Journal:  Nat Rev Genet       Date:  2021-07-07       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.